Tempus AI’s (TEM) Buy Rating Reaffirmed at HC Wainwright

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $85.00 price objective on the stock. HC Wainwright‘s target price points to a potential upside of 33.61% from the stock’s previous close.

TEM has been the subject of a number of other research reports. Roth Capital started coverage on Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price for the company. UBS Group started coverage on Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price target on the stock. Jefferies Financial Group upgraded Tempus AI from an “underperform” rating to a “hold” rating and raised their price target for the company from $35.00 to $70.00 in a report on Tuesday, November 3rd. BTIG Research lifted their price objective on Tempus AI from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Finally, Stifel Nicolaus lowered their price objective on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $79.37.

Read Our Latest Stock Analysis on TEM

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $63.62 on Thursday. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48. The firm has a 50 day simple moving average of $72.87 and a 200 day simple moving average of $57.56. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $89.09. The firm has a market cap of $11.60 billion, a P/E ratio of -60.02 and a beta of 3.61.

Tempus AI (NASDAQ:TEM – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. The firm had revenue of $411.54 million for the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.46) EPS. Sell-side analysts predict that Tempus AI will post -1.20 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In related news, CAO Ryan Bartolucci sold 7,062 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the transaction, the chief accounting officer owned 60,804 shares in the company, valued at approximately $4,560,300. The trade was a 10.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director directly owned 31,981 shares of the company’s stock, valued at $2,206,689. The trade was a 8.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 978,449 shares of company stock worth $72,226,961 over the last ninety days. 24.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. Pictet Asset Management Holding SA raised its stake in Tempus AI by 2,965.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after buying an additional 486,493 shares during the period. Eagle Health Investments LP bought a new position in Tempus AI during the first quarter worth about $11,588,000. First Trust Advisors LP grew its stake in Tempus AI by 90.3% in the third quarter. First Trust Advisors LP now owns 456,624 shares of the company’s stock valued at $37,397,000 after acquiring an additional 216,692 shares during the period. Aristotle Atlantic Partners LLC acquired a new position in Tempus AI in the first quarter valued at about $6,179,000. Finally, Public Sector Pension Investment Board acquired a new position in Tempus AI in the third quarter valued at about $9,992,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Further Reading

Analyst Recommendations for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.